Clinical implementation of pharmacogenetics in kidney transplantation: Calcineurin inhibitors in the starting blocks
(2014) British Journal of Clinical Pharmacology — Vol. 77, n° 4, p. 715-728 (2014)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 970.34 KB
Details
- Authors
- Abstract
- Pharmacogenetics has generated many expectations for its potential to individualize therapy proactively and improve medical care. However, despite the huge amount of reported genetic associations with either pharmacokinetics or pharmacodynamics of drugs, the translation into patient care is still slow. In fact, strong evidence for a substantial clinical benefit of pharmacogenetic testing is still limited, with a few exceptions. In kidney transplantation, established pharmacogenetic discoveries are being investigated for application in the clinic to improve efficacy and to limit toxicity associated with the use of immunosuppressive drugs, especially the frequently used calcineurin inhibitors (CNIs) tacrolimus and ciclosporin. The purpose of the present review is to picture the current status of CNI pharmacogenetics and to discuss the most promising leads that have been followed so far. © 2013 The British Pharmacological Society.
- Affiliations
Citations
Elens, L., Bouamar, R., Shuker, N., Hesselink, D. A., Van Gelder, T., & Van Schaik, R. H. N. (2014). Clinical implementation of pharmacogenetics in kidney transplantation: Calcineurin inhibitors in the starting blocks. British Journal of Clinical Pharmacology, 77(4), 715-728. https://doi.org/10.1111/bcp.12253 (Original work published 2014)